Tanvex BioPharma Inc (6541) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tanvex BioPharma Inc (6541) has a cash flow conversion efficiency ratio of -0.037x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-221.46 Million ≈ $-6.98 Million USD) by net assets (NT$6.00 Billion ≈ $189.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tanvex BioPharma Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Tanvex BioPharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 6541 total debt and obligations for a breakdown of total debt and financial obligations.
Tanvex BioPharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tanvex BioPharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YUEXIU SERVICES GROUP LTD
F:5R9
|
N/A |
|
Dabaco
VN:DBC
|
0.008x |
|
Perion Network
TA:PERI
|
0.009x |
|
Shanghai Xintonglian Packaging Co Ltd
SHG:603022
|
0.007x |
|
BlackRock California Municipal Income Closed Fund
NYSE:BFZ
|
-0.060x |
|
Guangdong Redwall New Materials Co Ltd
SHE:002809
|
0.003x |
|
Radiant Logistics Inc
NYSE MKT:RLGT
|
0.011x |
|
El Pollo Loco Holdings Inc
NASDAQ:LOCO
|
0.054x |
Annual Cash Flow Conversion Efficiency for Tanvex BioPharma Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Tanvex BioPharma Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Tanvex BioPharma Inc (6541) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$893.31 Million ≈ $28.14 Million |
NT$-1.15 Billion ≈ $-36.25 Million |
-1.288x | +26.24% |
| 2023-12-31 | NT$821.11 Million ≈ $25.87 Million |
NT$-1.43 Billion ≈ $-45.17 Million |
-1.746x | -82.16% |
| 2022-12-31 | NT$1.39 Billion ≈ $43.84 Million |
NT$-1.33 Billion ≈ $-42.02 Million |
-0.959x | -93.15% |
| 2021-12-31 | NT$2.79 Billion ≈ $88.05 Million |
NT$-1.39 Billion ≈ $-43.70 Million |
-0.496x | +27.24% |
| 2020-12-31 | NT$2.62 Billion ≈ $82.57 Million |
NT$-1.79 Billion ≈ $-56.32 Million |
-0.682x | -8.89% |
| 2019-12-31 | NT$3.03 Billion ≈ $95.49 Million |
NT$-1.90 Billion ≈ $-59.82 Million |
-0.626x | -64.42% |
| 2018-12-31 | NT$4.21 Billion ≈ $132.79 Million |
NT$-1.61 Billion ≈ $-50.59 Million |
-0.381x | -17.86% |
| 2017-12-31 | NT$3.75 Billion ≈ $118.12 Million |
NT$-1.21 Billion ≈ $-38.19 Million |
-0.323x | -38.59% |
| 2016-12-31 | NT$3.57 Billion ≈ $112.57 Million |
NT$-833.43 Million ≈ $-26.26 Million |
-0.233x | +50.64% |
| 2015-12-31 | NT$1.45 Billion ≈ $45.62 Million |
NT$-684.20 Million ≈ $-21.56 Million |
-0.473x | +35.83% |
| 2014-12-31 | NT$589.64 Million ≈ $18.58 Million |
NT$-434.17 Million ≈ $-13.68 Million |
-0.736x | -23.91% |
| 2013-12-31 | NT$403.64 Million ≈ $12.72 Million |
NT$-239.86 Million ≈ $-7.56 Million |
-0.594x | -- |
About Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that… Read more